MIRM

+ Watchlist + Portfolio

Mirum Pharmaceuticals, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $83.92
52-Week Range: $63.23 – $130.00
Market Cap: $5.38B
P/E (TTM): —
EPS (TTM): -14.10
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -702.97%
Return on Assets: -6.79%
Gross Margin: 81.73%
Operating Margin: -14.81%
Profit Margin: -139.18%
Current Ratio: 2.86
Debt/Equity: —
Total Debt: $762.95M
Free Cash Flow: $76.62M
Revenue Growth: 37.90%
Earnings Growth: —
Enterprise Value: $5.71B

MIRM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$77.06M	$186.37M	$336.89M	$521.31M
Cost of Revenue	$12.37M	$47.04M	$81.64M	$100.24M
Gross Profit	$64.69M	$139.34M	$255.25M	$421.07M
Research & Development	$106.84M	$102.61M	$140.63M	$186.18M
Selling, General & Admin	$89.07M	$145.88M	$202.22M	$257.03M
Operating Expenses	$195.91M	$248.49M	$342.85M	$443.21M
Operating Income	-$131.22M	-$109.15M	-$87.61M	-$22.14M
EBITDA	-$122.85M	-$136.49M	-$48.97M	$17.21M
Pretax Income	-$142.07M	-$162.42M	-$86.91M	-$21.43M
Income Tax	-$6.41M	$991.00K	$1.03M	$1.94M
Net Income	-$135.66M	-$163.41M	-$87.94M	-$23.36M
Diluted EPS	-4.02	-3.94	-1.85	-0.47
Diluted Shares	33.98M	40.89M	47.52M	50.20M

MIRM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.00M	$286.33M	$222.50M	$296.68M
Receivables	$23.99M	$67.97M	$78.29M	$123.33M
Inventory	$5.57M	$22.31M	$22.40M	$24.89M
Current Assets	$190.22M	$387.54M	$392.79M	$549.68M
Total Assets	$352.91M	$646.62M	$670.75M	$842.81M
Current Liabilities	$64.73M	$87.06M	$126.55M	$205.80M
Long-Term Debt	—	$306.42M	$308.08M	$309.80M
Total Debt	$2.19M	$308.14M	$317.76M	$319.45M
Total Liabilities	$210.87M	$397.95M	$445.11M	$528.12M
Retained Earnings	-$392.82M	-$556.24M	-$644.18M	-$667.54M
Shareholders' Equity	$142.04M	$248.67M	$225.64M	$314.69M
Working Capital	$125.50M	$300.48M	$266.24M	$343.88M
Net Debt	—	$20.09M	$85.58M	$13.11M

MIRM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$120.14M	-$70.94M	$10.32M	$55.83M
Capital Expenditure	-$278.00K	-$20.11M	-$20.99M	-$954.00K
Free Cash Flow	-$120.41M	-$91.05M	-$10.67M	$54.87M
Depreciation & Amortisation	$3.24M	$10.83M	$23.63M	$24.24M
Stock-Based Compensation	$27.01M	$35.02M	$48.44M	$71.42M
Investing Cash Flow	$7.70M	-$107.20M	-$90.13M	-$23.95M
Financing Cash Flow	$109.09M	$336.60M	$17.70M	$40.14M
Net Change in Cash	-$3.35M	$158.46M	-$62.10M	$72.02M

MIRM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$111.58M	$127.78M	$133.01M	$148.93M	$159.88M	$176.24M
Cost of Revenue	$23.02M	$23.42M	$25.54M	$28.26M	$28.80M	$30.35M
Gross Profit	$88.57M	$104.36M	$107.47M	$120.67M	$131.08M	$145.90M
Research & Development	$41.04M	$46.07M	$42.96M	$51.11M	$97.91M	$90.53M
Selling, General & Admin	$57.71M	$63.29M	$61.91M	$74.13M	$96.33M	$81.47M
Operating Expenses	$98.75M	$109.35M	$104.87M	$125.23M	$194.24M	$172.00M
Operating Income	-$10.18M	-$4.99M	$2.60M	-$4.57M	-$63.16M	-$26.10M
EBITDA	-$4.00M	$4.19M	$12.31M	$4.71M	-$779.19M	-$55.98M
Pretax Income	-$13.65M	-$5.46M	$2.64M	-$4.96M	-$789.68M	-$65.54M
Income Tax	$1.03M	$402.00K	-$262.00K	$767.00K	$475.00K	$1.69M
Net Income	-$14.68M	-$5.86M	$2.90M	-$5.73M	-$790.15M	-$67.23M
Diluted EPS	-0.30	-0.12	0.05	-0.11	-13.43	-1.06
Diluted Shares	48.89M	49.73M	56.99M	51.90M	58.85M	63.37M

MIRM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$211.82M	$228.12M	$282.02M	$296.68M	$324.91M	$330.73M
Receivables	$95.85M	$106.84M	$107.13M	$123.33M	$133.11M	$145.36M
Inventory	$22.42M	$22.94M	$24.02M	$24.89M	$25.52M	$25.77M
Current Assets	$410.82M	$453.40M	$530.58M	$549.68M	$569.44M	$636.31M
Total Assets	$690.25M	$725.83M	$785.12M	$842.81M	$890.92M	$1.04B
Current Liabilities	$127.58M	$144.80M	$160.36M	$205.80M	$272.82M	$222.79M
Long-Term Debt	$308.51M	$308.93M	$309.37M	$309.80M	$310.25M	$750.08M
Total Debt	$317.16M	$318.90M	$318.76M	$319.45M	$323.78M	$762.95M
Total Liabilities	$456.99M	$470.67M	$493.07M	$528.12M	$648.42M	$1.06B
Retained Earnings	-$658.86M	-$664.72M	-$661.81M	-$667.54M	-$1.46B	-$1.52B
Shareholders' Equity	$233.26M	$255.16M	$292.05M	$314.69M	$242.49M	-$10.42M
Working Capital	$283.24M	$308.60M	$370.22M	$343.88M	$296.61M	$413.52M
Net Debt	$96.69M	$80.81M	$27.35M	$13.11M	—	$419.35M

MIRM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.96M	$12.04M	$39.68M	$6.07M	-$228.76M	-$44.25M
Capital Expenditure	-$41.00K	-$126.00K	-$187.00K	-$600.00K	-$10.66M	-$25.02M
Free Cash Flow	-$2.00M	$11.91M	$39.49M	$5.47M	-$239.43M	-$69.28M
Depreciation & Amortisation	$6.05M	$6.06M	$6.06M	$6.07M	$6.87M	$6.94M
Stock-Based Compensation	$15.80M	$18.47M	$18.13M	$19.03M	$36.20M	$30.57M
Investing Cash Flow	-$16.13M	-$6.60M	-$2.23M	$1.01M	-$11.57M	-$159.99M
Financing Cash Flow	$6.36M	$8.69M	$16.10M	$9.00M	$270.08M	$211.44M
Net Change in Cash	-$11.74M	$14.13M	$53.55M	$16.07M	$29.75M	$7.20M

Market Snapshot

About

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. The company focuses on cholestatic liver conditions and other orphan hepatic disorders with high unmet medical needs.